BCL2 and acute myeloid leukemia: According to the NCCN guidelines, the BCL2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy not only for treatment-naïve elderly AML patients but also for relapsed or refractory AML patients deemed ineligible for intensive therapy (2, 3).